Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study.

"Duality of Interest. J.B. reports personal fees (advisory board and/or consultant fees) from Akcea Therapeutics, Amgen, Novartis, and Sanofi and research grants from Akcea Therapeutics, Amgen, and Sanofi outside of the submitted work. E.H. reports research grant funding from Sanofi, Pfizer, and Amgen, and consulting or honoraria from Amgen, Sanofi, Novartis, and Novo Nordisk. S.F. is an employee of AstraZeneca as of 4 October 2021. K.E.-O. reports personal lecturing fees/consultant fees from Abbott Diabetes Care, Eli Lilly and Company, Sanofi, and Novo Nordisk. B.E. has received personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Mundipharma, Navamedic, Novo Nordisk, and RLS Global and grants and personal fees from Sanofi outside the submitted work. No other potential conflicts of interest relevant to this article were reported."

"Funding. The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils (ALF-agreement, grant 83620). The NDR is financially supported by the Swedish Association of Local Authorities and Regions. E.H. received funding from the Swedish Heart-Lung foundation."